In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers

EJNMMI Research

Table 1 In vitro analysis of panitumumab F(ab')₂ conjugated with CHX-A"-DTPA.

	Chelate:mAb ratio (molar excess)
	Panitumumab F(ab') ₂				HuM195 F(ab') ₂
Analysis	0	5×	10×	20×	10×
IC₅₀ (nM)	0.5	0.6	0.7	0.7	0
Specific activity (mCi/mg)	-	1.9	14.8	2.9	9.4
Labeling yield (%)	-	13.9	49.4	24.4	50
Chelate:protein ratio	-	2.9	1.7	5.6	0.6
Percent binding	-	59.5	59.4	54.7	1.8